QuintilesIMS Named 2016 Frost & Sullivan Asia Pacific CRO Company of the Year
October 13 2016 - 11:00AM
Business Wire
Extends its leadership position with recently
completed merger
QuintilesIMS today was named Asia Pacific Contract Research
Organization (CRO) Company of the Year by Frost & Sullivan, a
leading business research and consulting firm, because of its
industry leadership and service delivery excellence. The evaluation
used in Frost & Sullivan’s selection was conducted before
Quintiles and IMS Health merged earlier this month.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161013006079/en/
QuintilesIMS honored as 2016 Frost &
Sullivan Asia Pacific CRO Company of the Year. (Photo: Business
Wire)
“The QuintilesIMS merger is another milestone in Quintiles’
history of leadership and innovation,” said Rhenu Bhuller, Partner,
Transformational Health, Frost & Sullivan. “Biopharma and
medtech companies are eager for innovative solutions to the complex
challenges they face – especially for evidence supporting outcomes
- and value-based care. QuintilesIMS is well-aligned to provide
those solutions."
The Frost & Sullivan Company of the Year Award evaluates
CROs on visionary innovation and performance as well as customer
impact. QuintilesIMS ranked highly in these categories, in
particular for pioneering new and complex areas such as
regenerative and personalized medicine. With this most recent
honor, Quintiles, now QuintilesIMS, has won the F&S CRO Company
of the Year award eight times in 10 years.
QuintilesIMS Asia Pacific President Anand Tharmaratnam said:
“This award belongs to our dedicated employees, and I believe Asia
Pac will be a global leader in 21st century healthcare innovation.
I’m excited about the new solutions QuintilesIMS can offer by
connecting clinical to commercial to real-world patient outcomes.
We are eager to lead Asia Pac’s transformation to become a center
for healthcare innovation.”
With a database of 18,500+ investigator sites or hospitals
across Asia Pacific, QuintilesIMS has conducted more than 1,250
studies covering a wide range of therapeutic areas – including
cardiovascular disease, oncology, neurology and infectious diseases
– involving 273,000 patients since 2000.
Over the last 12 months QuintilesIMS (formed by the recent
merger of Quintiles and IMS Health) has been named to Fortune
magazine’s “World’s Most Admired Companies” list for the second
consecutive year; recognized by the Ethisphere Institute as a 2016
World’s Most Ethical Company®; and named the industry leader in
Phase I, Phase II/III and Phase IV services by Industry Standard
Research’s 2016 CRO Quality Benchmarking reports, among other
honors.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and
technology-enabled healthcare service provider worldwide, dedicated
to helping its clients improve their clinical, scientific and
commercial results. Formed through the merger of Quintiles and IMS
Health, QuintilesIMS’s approximately 50,000 employees conduct
operations in more than 100 countries. Companies seeking to improve
real-world patient outcomes and enhanced clinical trial outsourcing
through treatment innovations, care provision and access can
leverage QuintilesIMS’s broad range of healthcare information,
technology and service solutions to drive new insights and
approaches. QuintilesIMS provides solutions that span clinical to
commercial bringing clients a unique opportunity to realize the
full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy,
QuintilesIMS uses healthcare data to deliver critical, real-world
disease and treatment insights. Through a wide variety of
privacy-enhancing technologies and safeguards, QuintilesIMS
protects individual privacy while managing information to drive
healthcare forward. These insights and execution capabilities
help biotech, medical device, and pharmaceutical companies, medical
researchers, government agencies, payers and other healthcare
stakeholders for the development and approval of new therapies,
identify unmet treatment needs and understand the safety,
effectiveness and value of pharmaceutical products in improving
overall health outcomes. To learn more, visit
www.QuintilesIMS.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013006079/en/
QuintilesIMSMedia Relations:Jay Johnson,
+65.9655.6635jay.johnson@quintilesims.comorTor Constantino,
+1.484.567.6732tor.constantino@quintilesims.comorInvestor
Relations:Tom Kinsley,
+1.203.448.4691tom.kinsley@quintilesims.comorTodd Kasper,
+1.919.998.2590todd.kasper@quintilesims.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024